{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:10:24Z","timestamp":1794028224560,"version":"4.8.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.beem.2021.101490","type":"journal-article","created":{"date-parts":[[2021,2,7]],"date-time":"2021-02-07T00:42:16Z","timestamp":1612658536000},"page":"101490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Updates in adrenal steroidogenesis inhibitors for Cushing\u2019s syndrome \u2013 A practical guide"],"prefix":"10.1016","volume":"35","author":[{"given":"Elena V.","family":"Varlamov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley J.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fleseriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.beem.2021.101490_bib1","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1210\/jc.2008-0125","article-title":"The diagnosis of cushing\u2019s syndrome: an endocrine society clinical practice guideline","volume":"93","author":"Nieman","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2021.101490_bib2","doi-asserted-by":"crossref","first-page":"101380","DOI":"10.1016\/j.beem.2020.101380","article-title":"Cushing\u2019s syndrome: overview of clinical presentation, diagnostic tools and complications","volume":"34","author":"Barbot","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"issue":"6","key":"10.1016\/j.beem.2021.101490_bib3","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1210\/jc.2012-3582","article-title":"Multisystem morbidity and mortality in Cushing\u2019s syndrome: a cohort study","volume":"98","author":"Dekkers","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2021.101490_bib4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11102-016-0742-1","article-title":"Updates on the role of adrenal steroidogenesis inhibitors in Cushing\u2019s syndrome: a focus on novel therapies","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"issue":"8","key":"10.1016\/j.beem.2021.101490_bib5","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of cushing\u2019s syndrome: an endocrine society clinical practice guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2021.101490_bib6","doi-asserted-by":"crossref","first-page":"101270","DOI":"10.1016\/j.beem.2019.04.004","article-title":"Therapeutic options after surgical failure in Cushing\u2019s disease: a critical review","volume":"33","author":"Rubinstein","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"issue":"1","key":"10.1016\/j.beem.2021.101490_bib7","first-page":"30","article-title":"Functioning pituitary adenomas - current treatment options and emerging medical therapies","volume":"15","author":"Varlamov","year":"2019","journal-title":"Eur Endocrinol"},{"issue":"10","key":"10.1016\/j.beem.2021.101490_bib8","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1056\/NEJMra1810772","article-title":"Pituitary-tumor endocrinopathies","volume":"382","author":"Melmed","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.beem.2021.101490_bib9","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40265-019-01128-7","article-title":"Medical management of cushing\u2019s syndrome: current and emerging treatments","volume":"79","author":"Hinojosa-Amaya","year":"2019","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.beem.2021.101490_bib10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/17446651.2020.1802243","article-title":"Management of patients with persistent or recurrent Cushing\u2019s disease after initial pituitary surgery","volume":"15","author":"Capatina","year":"2020","journal-title":"Expet Rev Endocrinol Metabol"},{"issue":"7","key":"10.1016\/j.beem.2021.101490_bib11","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","article-title":"Treatment of adrenocorticotropin-dependent Cushing\u2019s syndrome: a consensus statement","volume":"93","author":"Biller","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2021.101490_bib12","doi-asserted-by":"crossref","first-page":"R263","DOI":"10.1530\/EJE-14-1014","article-title":"Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing\u2019s syndrome","volume":"172","author":"Daniel","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2021.101490_bib13","doi-asserted-by":"crossref","first-page":"R19","DOI":"10.1530\/JOE-14-0300","article-title":"Treatment of Cushing\u2019s disease: a mechanistic update","volume":"223","author":"Cuevas-Ramos","year":"2014","journal-title":"J\u00a0Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2021.101490_bib14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ecl.2018.01.006","article-title":"Medical therapy for cushing\u2019s syndrome in the twenty-first century","volume":"47","author":"Tritos","year":"2018","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"4","key":"10.1016\/j.beem.2021.101490_bib15","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1210\/jc.2013-2117","article-title":"LCI699, a potent 11 beta-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing\u2019s disease: results from a multicenter, proof-of-concept study","volume":"99","author":"Bertagna","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2021.101490_bib16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11102-015-0692-z","article-title":"Osilodrostat, a potent oral 11 beta-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing\u2019s disease","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"issue":"9","key":"10.1016\/j.beem.2021.101490_bib17","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","article-title":"Efficacy and safety of osilodrostat in patients with Cushing\u2019s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase","volume":"8","author":"Pivonello","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.beem.2021.101490_bib18","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1507\/endocrj.EJ19-0617","article-title":"A\u00a0multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11 beta-hydroxylase inhibitor, in Japanese patients with endogenous Cushing\u2019s syndrome other than Cushing\u2019s disease","volume":"67","author":"Tanaka","year":"2020","journal-title":"Endocr J"},{"key":"10.1016\/j.beem.2021.101490_bib19","series-title":"Isturisa (Osilodrostat) tablets, for oral use. [package insert]","year":"2020"},{"key":"10.1016\/j.beem.2021.101490_bib20","series-title":"[package insert]","year":"2010"},{"key":"10.1016\/j.beem.2021.101490_bib21","series-title":"[package insert]","year":"2013"},{"key":"10.1016\/j.beem.2021.101490_bib22","series-title":"Lysodren (mitotane) tablets, for oral use. [package insert]","year":"2019"},{"key":"10.1016\/j.beem.2021.101490_bib23","series-title":"Lexi-drugs online [database on the Internet]","author":"Etomidate","year":"2016"},{"issue":"5","key":"10.1016\/j.beem.2021.101490_bib25","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40261-017-0497-0","article-title":"Drug interaction potential of osilodrostat (LCI699) based on its effect on the pharmacokinetics of probe drugs of cytochrome P450 enzymes in healthy adults","volume":"37","author":"Armani","year":"2017","journal-title":"Clin Drug Invest"},{"issue":"6","key":"10.1016\/j.beem.2021.101490_bib26","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/00000542-198806000-00014","article-title":"Effect of etomidate on hepatic drug metabolism in humans","volume":"68","author":"Atiba","year":"1988","journal-title":"Anesthesiology"},{"issue":"11","key":"10.1016\/j.beem.2021.101490_bib27","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s00134-008-1264-8","article-title":"Opioid and benzodiazepine contributions to etomidate-associated adrenal insufficiency","volume":"34","author":"Daniell","year":"2008","journal-title":"Intensive Care Med"},{"issue":"11","key":"10.1016\/j.beem.2021.101490_bib28","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2213-8587(19)30313-4","article-title":"Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing\u2019s syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial","volume":"7","author":"Fleseriu","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2021.101490_bib29","series-title":"Drug interactions: cytochrome P450 drug interaction table","author":"Flockhart","year":"2007"},{"issue":"1","key":"10.1016\/j.beem.2021.101490_bib30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0090-9556(24)15008-8","article-title":"Effect of the adrenal 11-beta-hydroxylase inhibitor metyrapone on human hepatic cytochrome P-450 expression: induction of cytochrome P-450 3A4","volume":"28","author":"Harvey","year":"2000","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.beem.2021.101490_bib31","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2265.2011.04214.x","article-title":"Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma","volume":"75","author":"Kroiss","year":"2011","journal-title":"Clin Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2021.101490_bib32","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.4158\/EP15686.CR","article-title":"Co-administration of the CYP3A4 inhibitor diltiazem counteracts mitotane-induced clearance of glucocorticoids and antihypertensives in a patient with adrenocortical carcinoma","volume":"2","author":"Minami","year":"2016","journal-title":"AACE Clin Case Reports"},{"key":"10.1016\/j.beem.2021.101490_bib33","series-title":"Applied clinical pharmacokinetics and pharmacodynamics of psychopharmacological agents","article-title":"Mw J. Clinically significant interactions with anesthetic agents","author":"Jann","year":"2016"},{"issue":"7","key":"10.1016\/j.beem.2021.101490_bib34","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1021\/acs.biochem.8b01221","article-title":"Interaction of human drug-metabolizing CYP3A4 with small inhibitory molecules","volume":"58","author":"Sevrioukova","year":"2019","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/j.beem.2021.101490_bib35","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1530\/EJE-10-0956","article-title":"Mitotane has a strong and a durable inducing effect on CYP3A4 activity","volume":"164","author":"van Erp","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2021.101490_bib36","author":"Woosley"},{"issue":"1","key":"10.1016\/j.beem.2021.101490_bib37","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1210\/jc.2006-1328","article-title":"Corticotroph tumor progression after adrenalectomy in Cushing\u2019s Disease: a reappraisal of Nelson\u2019s Syndrome","volume":"92","author":"Assie","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2021.101490_bib38","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ecl.2020.05.004","article-title":"Nelson\u2019s syndrome: an update","volume":"49","author":"Fountas","year":"2020","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"10","key":"10.1016\/j.beem.2021.101490_bib39","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1210\/jc.2014-1843","article-title":"Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing\u2019s disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone","volume":"99","author":"Fleseriu","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.beem.2021.101490_bib40","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2013-3628","article-title":"Ketoconazole in Cushing\u2019s disease: is it worth a try?","volume":"99","author":"Castinetti","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2021.101490_bib41","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1530\/EJE-12-0358","article-title":"Efficiency and tolerance of mitotane in Cushing\u2019s disease in 76 patients from a single center","volume":"167","author":"Baudry","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2021.101490_bib42","article-title":"Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing\u2019s disease","volume":"Oct 19","author":"Fontaine-Sylvestre","year":"2020","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.beem.2021.101490_bib43","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1124\/jpet.110.167148","article-title":"Pharmacodynamic and pharmacokinetic characterization of the aldosterone synthase inhibitor FAD286 in two rodent models of hyperaldosteronism: comparison with the 11 beta-hydroxylase inhibitor metyrapone","volume":"334","author":"Rigel","year":"2010","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"issue":"2","key":"10.1016\/j.beem.2021.101490_bib44","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2265.1991.tb03517.x","article-title":"Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing\u2019s syndrome","volume":"35","author":"Verhelst","year":"1991","journal-title":"Clin Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2021.101490_bib45","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/cen.12286","article-title":"Increased long-term remission after adequate medical cortisol suppression therapy as presurgical treatment in Cushing\u2019s disease","volume":"80","author":"van den Bosch","year":"2014","journal-title":"Clin Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2021.101490_bib46","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1365-2265.2012.04424.x","article-title":"A\u00a0reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing\u2019s syndrome","volume":"77","author":"Valassi","year":"2012","journal-title":"Clin Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2021.101490_bib47","first-page":"451","article-title":"Aminoglutethimide and metyrapone in the management of Cushing\u2019s syndrome","volume":"109","author":"Thoren","year":"1985","journal-title":"Acta Endocrinol"},{"issue":"6081","key":"10.1016\/j.beem.2021.101490_bib48","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/bmj.2.6081.215","article-title":"Metyrapone in long-term management of Cushing\u2019s disease","volume":"2","author":"Jeffcoate","year":"1977","journal-title":"Br Med J"},{"issue":"11","key":"10.1016\/j.beem.2021.101490_bib49","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1210\/jc.2015-2616","article-title":"Effectiveness of metyrapone in treating cushing\u2019s syndrome: a retrospective multicenter study in 195 patients","volume":"100","author":"Daniel","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2021.101490_bib50","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s12020-018-1675-4","article-title":"Metyrapone treatment in Cushing\u2019s syndrome: a real-life study","volume":"62","author":"Ceccato","year":"2018","journal-title":"Endocrine"},{"issue":"4","key":"10.1016\/j.beem.2021.101490_bib51","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1210\/er.2013-1048","article-title":"The treatment of cushing\u2019s disease","volume":"36","author":"Pivonello","year":"2015","journal-title":"Endocr Rev"},{"issue":"7","key":"10.1016\/j.beem.2021.101490_bib53","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1530\/EC-18-0400","article-title":"Preoperative treatment with metyrapone in patients with cushing\u2019s syndrome due to adrenal adenoma","volume":"1","author":"Puglisi","year":"2018","journal-title":"Endocr Connect"},{"issue":"1","key":"10.1016\/j.beem.2021.101490_bib54","doi-asserted-by":"crossref","first-page":"bvaa167","DOI":"10.1210\/jendso\/bvaa167","article-title":"Adrenal cushing syndrome diagnosed during pregnancy: successful medical management with metyrapone","volume":"5","author":"Azzola","year":"2021","journal-title":"J\u00a0Endocr Soc"},{"issue":"3","key":"10.1016\/j.beem.2021.101490_bib55","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2265.1993.tb02380.x","article-title":"ACTH-independent Cushing\u2019s syndrome in pregnancy with spontaneous resolution after delivery: control of the hypercortisolism with metyrapone","volume":"39","author":"Close","year":"1993","journal-title":"Clin Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2021.101490_bib56","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1210\/jc.2004-2361","article-title":"Cushing\u2019s syndrome during pregnancy: personal experience and review of the literature","volume":"90","author":"Lindsay","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2021.101490_bib57","first-page":"26","article-title":"Ketoconazole therapy: an efficacious alternative to achieve eucortisolism in patients with Cushing\u2019s syndrome","volume":"67","author":"Moncet","year":"2007","journal-title":"Medicina (B Aires)"},{"issue":"4","key":"10.1016\/j.beem.2021.101490_bib58","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2265.1991.tb03547.x","article-title":"Ketoconazole treatment in Cushing\u2019s syndrome: experience in 34 patients","volume":"35","author":"Sonino","year":"1991","journal-title":"Clin Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2021.101490_bib59","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.1995.13.1.157","article-title":"Ketoconazole in the management of paraneoplastic Cushing\u2019s syndrome secondary to ectopic adrenocorticotropin production","volume":"13","author":"Winquist","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.beem.2021.101490_bib60","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1530\/EJE-07-0514","article-title":"Ketoconazole revisited: a preoperative or postoperative treatment in Cushing\u2019s disease","volume":"158","author":"Castinetti","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2021.101490_bib61","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1530\/EJE-17-0886","article-title":"Hepatic safety of ketoconazole in Cushing\u2019s syndrome: results of a Compassionate Use Programme in France","volume":"178","author":"Young","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2021.101490_bib62","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/archinte.1984.00350170237037","article-title":"Fatal hepatitis associated with ketoconazole therapy","volume":"144","author":"Duarte","year":"1984","journal-title":"Arch Intern Med"},{"issue":"6569","key":"10.1016\/j.beem.2021.101490_bib63","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/bmj.294.6569.419","article-title":"Hepatic reactions associated with ketoconazole in the United Kingdom","volume":"294","author":"Lake-Bakaar","year":"1987","journal-title":"Br Med J"},{"issue":"3","key":"10.1016\/j.beem.2021.101490_bib64","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0016-5085(84)80021-9","article-title":"Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases","volume":"86","author":"Lewis","year":"1984","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.beem.2021.101490_bib65","first-page":"277","article-title":"Ketoconazole-induced liver damage","volume":"58","author":"Findor","year":"1998","journal-title":"Medicina (B Aires)"},{"issue":"5","key":"10.1016\/j.beem.2021.101490_bib66","first-page":"e239","article-title":"Caution advised using combination ketoconazole and Pd-1 inhibitors","volume":"6","author":"Yang","year":"2020","journal-title":"AACE Clin Case Rep"},{"issue":"5","key":"10.1016\/j.beem.2021.101490_bib67","doi-asserted-by":"crossref","first-page":"L1","DOI":"10.1530\/EJE-18-0694","article-title":"Should we avoid using ketoconazole in patients with severe Cushing\u2019s syndrome and increased levels of liver enzymes?","volume":"179","author":"Ollivier","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2021.101490_bib68","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1210\/endo-122-2-618","article-title":"Ketoconazole inhibits corticotropic cell function in\u00a0vitro","volume":"122","author":"Stalla","year":"1988","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.beem.2021.101490_bib69","first-page":"185","article-title":"In\u00a0vitro effects of ketoconazole on corticotrope cell morphology and ACTH secretion of two pituitary adenomas removed from patients with Nelson\u2019s syndrome","volume":"121","author":"Jimenez Reina","year":"1989","journal-title":"Acta Endocrinol"},{"issue":"Suppl 1","key":"10.1016\/j.beem.2021.101490_bib70","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000314292","article-title":"Medical treatment of Cushing\u2019s syndrome: adrenal-blocking drugs and ketaconazole","volume":"92","author":"Feelders","year":"2010","journal-title":"Neuroendocrinology"},{"issue":"4","key":"10.1016\/j.beem.2021.101490_bib71","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2265.1987.tb01174.x","article-title":"Response of pituitary-adrenal axis to corticotrophin releasing hormone in patients with Cushing\u2019s disease before and after ketoconazole treatment","volume":"27","author":"Boscaro","year":"1987","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2021.101490_bib72","first-page":"58","article-title":"Effect of ketoconazole on CRH-induced ACTH and cortisol release in patients with Cushing\u2019s disease","volume":"16","author":"Berselli","year":"1987","journal-title":"Horm Metab Res Suppl"},{"key":"10.1016\/j.beem.2021.101490_bib73","series-title":"2S,4R-Ketoconazole is the relevant enantiomer of ketoconazole for cortisol synthesis inhibition: steroidogenic P450s inhibition involves multiple mechanisms","author":"Auchus","year":"2018"},{"key":"10.1016\/j.beem.2021.101490_bib74","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s11102-020-01103-6","article-title":"Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing\u2019s syndrome","volume":"24","author":"Geer","year":"2021","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.beem.2021.101490_bib75","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/ALN.0b013e3181ff72b5","article-title":"Clinical and molecular pharmacology of etomidate","volume":"114","author":"Forman","year":"2011","journal-title":"Anesthesiology"},{"issue":"2","key":"10.1016\/j.beem.2021.101490_bib76","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/0039-128X(93)90054-Q","article-title":"Direct inhibitory effect of etomidate on corticosteroid secretion in human pathologic adrenocortical cells","volume":"58","author":"Varga","year":"1993","journal-title":"Steroids"},{"issue":"22","key":"10.1016\/j.beem.2021.101490_bib77","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJM198405313102202","article-title":"Inhibition of adrenal steroidogenesis by the anesthetic etomidate","volume":"310","author":"Wagner","year":"1984","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.beem.2021.101490_bib78","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1530\/EJE-12-0274","article-title":"Etomidate in the management of hypercortisolaemia in Cushing\u2019s syndrome: a review","volume":"167","author":"Preda","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2021.101490_bib79","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11102-011-0314-3","article-title":"Medical suppression of hypercortisolemia in Cushing\u2019s syndrome with particular consideration of etomidate","volume":"15","author":"Heyn","year":"2012","journal-title":"Pituitary"},{"issue":"Suppl 3","key":"10.1016\/j.beem.2021.101490_bib80","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1046\/j.1365-2362.2000.0300s3076.x","article-title":"New mechanisms of adrenostatic compounds in a human adrenocortical cancer cell line","volume":"30","author":"Fassnacht","year":"2000","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"10.1016\/j.beem.2021.101490_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/js.2018-00269","article-title":"Continuous etomidate infusion for the management of severe cushing syndrome: validation of a standard protocol","volume":"3","author":"Carroll","year":"2019","journal-title":"J\u00a0Endocr Soc"},{"issue":"2","key":"10.1016\/j.beem.2021.101490_bib82","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1530\/EJE-20-0380","article-title":"Etomidate infusion at low doses is an effective and safe treatment for severe Cushing\u2019s syndrome outside intensive care","volume":"183","author":"Constantinescu","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2021.101490_bib83","doi-asserted-by":"crossref","DOI":"10.1177\/2042018819825541","article-title":"Low-dose etomidate for the management of severe hypercortisolaemia in different clinical scenarios: a case series and review of the literature","volume":"10","author":"Lebek-Szatanska","year":"2019","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"21","key":"10.1016\/j.beem.2021.101490_bib84","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/BF01711723","article-title":"Adrenocortical suppression by a single induction dose of etomidate","volume":"62","author":"Allolio","year":"1984","journal-title":"Klin Wochenschr"},{"issue":"4","key":"10.1016\/j.beem.2021.101490_bib85","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/00000542-197810000-00010","article-title":"Pharmacokinetics of etomidate, a new intravenous anesthetic","volume":"49","author":"Van Hamme","year":"1978","journal-title":"Anesthesiology"},{"issue":"5","key":"10.1016\/j.beem.2021.101490_bib86","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1210\/jcem-70-5-1426","article-title":"Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing\u2019s syndrome and dose-response relationship in normal subjects","volume":"70","author":"Schulte","year":"1990","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.beem.2021.101490_bib87","first-page":"3542","article-title":"Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing\u2019s syndrome and peritonitis","volume":"83","author":"Drake","year":"1998","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2021.101490_bib88","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00000542-198607000-00004","article-title":"Increased sensitivity to etomidate in the elderly: initial distribution versus altered brain response","volume":"65","author":"Arden","year":"1986","journal-title":"Anesthesiology"},{"issue":"4","key":"10.1016\/j.beem.2021.101490_bib89","first-page":"171","article-title":"Plasma protein binding of etomidate in different age groups and in patients with chronic respiratory insufficiency","volume":"19","author":"Carlos","year":"1981","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"issue":"9","key":"10.1016\/j.beem.2021.101490_bib90","first-page":"4104","article-title":"Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing\u2019s syndrome","volume":"86","author":"Krakoff","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2021.101490_bib91","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00000542-199901000-00017","article-title":"Reducing myoclonus after etomidate","volume":"90","author":"Doenicke","year":"1999","journal-title":"Anesthesiology"},{"issue":"5","key":"10.1016\/j.beem.2021.101490_bib92","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/j.1875-9114.1983.tb03266.x","article-title":"Etomidate: a new intravenous anesthetic induction agent","volume":"3","author":"Giese","year":"1983","journal-title":"Pharmacotherapy"},{"issue":"9","key":"10.1016\/j.beem.2021.101490_bib93","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1210\/jc.2011-0536","article-title":"Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing\u2019s syndrome","volume":"96","author":"Kamenicky","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2021.101490_bib94","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1530\/EJE-14-0913","article-title":"Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole","volume":"172","author":"Corcuff","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2021.101490_bib95","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11102-013-0475-3","article-title":"Combination therapy for Cushing\u2019s disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole?","volume":"17","author":"Barbot","year":"2014","journal-title":"Pituitary"},{"issue":"19","key":"10.1016\/j.beem.2021.101490_bib96","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMc1000094","article-title":"Pasireotide alone or with cabergoline and ketoconazole in Cushing\u2019s disease","volume":"362","author":"Feelders","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.beem.2021.101490_bib97","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11102-009-0209-8","article-title":"Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing\u2019s disease","volume":"13","author":"Vilar","year":"2010","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2021.101490_bib98","first-page":"859","article-title":"PROMPT: a prospective study to assess efficacy and safety of metyrapone in endogenous Cushing\u2019s syndrome","volume":"56","author":"Nieman","year":"2018","journal-title":"Endocrine Abstracts"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X21000075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X21000075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:56:40Z","timestamp":1761497800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X21000075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1521690X21000075"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2021.101490","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates in adrenal steroidogenesis inhibitors for Cushing\u2019s syndrome \u2013 A practical guide","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2021.101490","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101490"}}